Rory Smoot (@RorySmoot78) profile picture

Hepatobiliary Surgeon | Surgeon Scientist

Minnesota, USA
Joined May 2017
Photo by Rory Smoot (@RorySmoot78)Photo by Rory Smoot (@RorySmoot78)Photo by Rory Smoot (@RorySmoot78)Photo by Rory Smoot (@RorySmoot78)
In this paper in press, we demonstrate a dual role of TRAIL-TRAIL-R in #CCA 👉🏼 Noncanonical TRAIL signaling augments MDSC abundance 👉🏼 Canonical TRAIL signaling promotes CCA cell apoptosis but is less potent 👉🏼MDSC are resistant to TRAIL-induced apoptosis bit.ly/449CnL9
Study finds noncanonical TRAIL signaling promotes myeloid-derived suppressor cell abundance and tumor growth in #cholangiocarcinoma. 🌟 Learn more at ow.ly/q8nG50Ri9ra
2
4
30
3,362
Fantastic presentation by Dr. Jennifer Tomlinson, a talented surgery resident, at the Cholangiocarcinoma Foundation Meeting highlighting her work on targeting TEADs.
1
13
32
3,874
The inaugural Basic science track day at the @curecc Annual Conference is off to a great start. Fantastic first session with remarkable speakers and robust discussion focused on nanoparticles, adoptive cell therapy, innovative models, and CCA multiomics. @siadaniela @LesinskiLab
4
18
900
Excited to share some our latest research. doi.org/10.1093/pnasnexus/pg…
2
6
652
It’s Cholangiocarcinoma Awareness month. Our growing #CCA discovery science team celebrated #WorldCCADAY. 5 teams under one #CCA umbrella all with one mission: to improve outcomes for our CCA patients. #greenforCCA @curecc
1
5
1
35
3,003
Rory Smoot retweeted
Happy to see friends and mentees teaming up to produce a nice piece.
This Post is from an account that no longer exists. Learn more
2
5
1,673
Post doctoral fellow Dr. Shohei Takaichi presenting his work unraveling resistance mechanisms in #cholangiocarcinoma at #AACR2023. @curecc @MayoClinicSurg @MayoCancerCare
5
12
1,036
Another great contribution from the Guggenheim 17 family. #Senescence in cholangiocytes via ETS1. #PSC ⁦@NFLaRussoMD⁩ ⁦@MedCityGirl⁩ ⁦@MayoClinicGIHep⁩ gastrojournal.org/article/S0…
2
249
New @TheLancet - Kelley et al - Pembrolizumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) thelancet.com/journals/lance… #gitwitter #onctwitter
5
1
29
29,340
A talented research technician from my group, Danielle Carlson, presenting our data on targeting hsf1 activity in #cholangiocarcinoma patient-derived xenografts. #aacr2023 @curecc @MayoClinicSurg @MayoCancerCare
7
19
1,726
Dr. Tomlinson presenting our work with aptamer targeted RNA therapeutics for #cholangiocarcinoma #AACR2023 @curecc @MayoClinicSurg @MayoCancerCare
1
10
36
3,176
1/3🚀JHEP Twittorial🚀 ☘️A step forward for targeting Hippo pathway in CCA 🔓👉https://xitter.cf/t.co/fqfe91JyFo CCAs 👉⬆️activity of oncogenic LCK (Src family tyrosine kinase)/YAP (Yes-associated protein) dependent Hippo path Hippo💊👉challenge Rory L. Smoot & cols👇👇 #livertwitter
3
9
18
4,823